Aggressive Lymphomas
From the Journals
CAR T-cell therapy neurotoxicity linked to NfL elevations
Even prior to CAR T-cell therapy, patients developing related neurotoxic complications show elevated markers of neuronal injury.
Conference Coverage
Many die waiting for `last-chance’ therapy
Blood cancer patients, especially those with myeloma, face hospice and death while awaiting CAR T-cell therapy.
News from the FDA/CDC
FDA withdraws lymphoma drug approval after investigation
Last February, the FDA said it was investigating a possible increased risk of death associated with umbralisib. Five months later, the results are...
From the Journals
Clozapine and cancer risk in schizophrenia patients: New data
The clozapine-related risk increase was specific to hematological malignancies only.
Feature
Ex–hospital porter a neglected giant of cancer research
An Indian immigrant who once emptied bedpans in a Boston hospital went on to become the “father of chemotherapy.”
From the Journals
First-line CAR T-cell therapy could help cure some lymphomas
Axi-cel is already approved for some forms of relapsed/refractory lymphoma, and a new phase 2 study hints that it has potential as a frontline...
Feature
100 coauthored papers, 10 years: Cancer transplant pioneers model 'team science'
MSKCC medical oncologists share expertise in HSCT, Spanish background, a gift for mentoring, and 100 peer-reviewed publications written together...
Feature
DKMS: Small nonprofit to world’s largest stem cell donor registry
A German family’s tragedy launched DKMS, a multinational organization whose goal is to “delete blood cancer.”
Conference Coverage
NHL: As a second-line treatment in phase 3 trial, tisa-cel disappoints
In this phase 3 BELINDA study, CAR T-cell therapy did not prolong event-free survival as a second-line treatment of aggressive non-Hodgkin...
From the Journals
Don’t delay: Cancer patients need both doses of COVID vaccine
For patients with cancer, immune response to the first dose of the Pfizer COVID-19 vaccine is reduced, and there is a need for a booster dose at...
Feature
CDER chief reflects on advances in rare diseases
“People always call me fearless, but I feel like I just state the facts,” Dr. Janet Woodcock said.